Page 1834 - Hematology_ Basic Principles and Practice ( PDFDrive )

1632.e4 Part X Transplantation

123. Maguire HC, Jr, Maibach HI, Minisce LW, Jr: Inhibition of guinea pig 143. Chen BJ, Cui X, Liu C, et al: Prevention of graft-versus-host disease
anaphylactic sensitization with cyclophosphoramide. J Invest Dermatol while preserving graft-versus-leukemia effect after selective depletion
36:235–236, 1961. of host-reactive T cells by photodynamic cell purging process. Blood
124. Berenbaum MC, Brown IN: Prolongation of homograft survival in 99(9):3083–3088, 2002.
mice with single doses of cyclophosphamide. Nature 200:84, 1963. 144. Guimond M, Balassy A, Barrette M, et al: P-glycoprotein targeting: a
125. Mayumi H, Tokunaga K: Cyclophosphamide-induced chimera-type unique strategy to selectively eliminate immunoreactive T cells. Blood
tolerance to allografts: an overview of drug-induced immunological 100(2):375–382, 2002.
tolerance. Fukuoka Igaku Zasshi 81(1):20–39, 1990. 145. Bastien JP, Krosl G, Therien C, et al: Photodepletion differentially
+
+
126. Mayumi H, Umesue M, Nomoto K: Cyclophosphamide-induced affects CD4 Tregs versus CD4 effector T cells from patients with
immunological tolerance: an overview. Immunobiology 195(2):129–139, chronic graft-versus-host disease. Blood 116(23):4859–4869, 2010.
1996. 146. Bastien JP, Roy J, Roy DC: Selective T-cell depletion for haplotype-
127. Eto M, Mayumi H, Tomita Y, et al: Sequential mechanisms of mismatched allogeneic stem cell transplantation. Semin Oncol
cyclophosphamide-induced skin allograft tolerance including the 39(6):674–682, 2012.
intrathymic clonal deletion followed by late breakdown of the clonal 147. O’Donnell PV, Luznik L, Jones RJ, et al: Nonmyeloablative bone
deletion. J Immunol 145(5):1303–1310, 1990. marrow transplantation from partially HLA-mismatched related donors
128. Kong YY, Eto M, Omoto K, et al: Regulatory T cells in maintenance and using posttransplantation cyclophosphamide. Biol Blood Marrow Trans-
reversal of peripheral tolerance in vivo. J Immunol 157(12):5284–5289, plant 8(7):377–386, 2002.
1996. 148. Luznik L, O’Donnell PV, Symons HJ, et al: HLA-haploidentical bone
129. Nomoto K, Eto M, Yanaga K, et al: Interference with cyclophosphamide- marrow transplantation for hematologic malignancies using nonmy-
induced skin allograft tolerance by cyclosporin A. J Immunol eloablative conditioning and high-dose, posttransplantation cyclophos-
149(8):2668–2674, 1992. phamide. Biol Blood Marrow Transplant 14(6):641–650, 2008.
130. Dukor P, Dietrich FM: Prevention of cyclophosphamide-induced toler- 149. Luznik L, O’Donnell PV, Fuchs EJ: Post-transplantation cyclophos-
ance to erythrocytes by pretreatment with cortisone. Proc Soc Exp Biol phamide for tolerance induction in HLA-haploidentical bone marrow
Med 133(1):280–285, 1970. transplantation. Semin Oncol 39(6):683–693, 2012.
131. Nishimura Y, Mayumi H, Tomita Y, et al: Recombinant human 150. Munchel A, Kesserwan C, Symons HJ, et al: Nonmyeloablative,
granulocyte colony-stimulating factor improves the compromised state HLA-haploidentical bone marrow transplantation with high dose,
of recipient mice without affecting the induction of specific toler- post-transplantation cyclophosphamide. Pediatr Rep 3(Suppl 2):e15,
ance in the cyclophosphamide-induced tolerance system. J Immunol 2011.
146(8):2639–2647, 1991. 151. Kasamon YL, Luznik L, Leffell MS, et al: Nonmyeloablative HLA-
132. Colson YL, Wren SM, Schuchert MJ, et al: A nonlethal condition- haploidentical bone marrow transplantation with high-dose posttrans-
ing approach to achieve durable multilineage mixed chimerism and plantation cyclophosphamide: effect of HLA disparity on outcome. Biol
tolerance across major, minor, and hematopoietic histocompatibility Blood Marrow Transplant 16(4):482–489, 2010.
barriers. J Immunol 155(9):4179–4188, 1995. 152. McCurdy SR, Kanakry JA, Showel MM, et al: Risk-stratified outcomes
133. Luznik L, Jalla S, Engstrom LW, et al: Durable engraftment of major of nonmyeloablative, HLA-haploidentical BMT with high-dose post-
histocompatibility complex-incompatible cells after nonmyeloablative transplantation cyclophosphamide. Blood 125:3024, 2015.
conditioning with fludarabine, low-dose total body irradiation, and 153. Raiola A, Dominietto A, Varaldo R, et al: Unmanipulated haploi-
posttransplantation cyclophosphamide. Blood 98(12):3456–3464, dentical BMT following non-myeloablative conditioning and post-
2001. transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow
134. Colson YL, Li H, Boggs SS, et al: Durable mixed allogeneic chimerism Transplant 49:190, 2014.
and tolerance by a nonlethal radiation-based cytoreductive approach. 154. Solomon SR, Sizemore CA, Sanacore M, et al: Haploidentical trans-
J Immunol 157(7):2820–2829, 1996. plantation using T cell replete peripheral blood stem cells and myeloab-
135. Luznik L, Engstrom LW, Iannone R, et al: Posttransplantation lative conditioning in patients with high-risk hematologic malignancies
cyclophosphamide facilitates engraftment of major histocompatibility who lack conventional donors is well tolerated and produces excellent
complex-identical allogeneic marrow in mice conditioned with low- relapse-free survival: results of a prospective phase II trial. Biol Blood
dose total body irradiation. Biol Blood Marrow Transplant 8:131, Marrow Transplant 18(12):1859–1866, 2012.
2002. 155. Solomon SR, Sizemore CA, Sanacore M, et al: Total body irradiation-
136. Ross D, Jones M, Komanduri K, et al: Antigen and lymphopenia-driven based myeloablative haploidentical stem cell transplantation is a safe
donor T cells are differentially diminished by post-transplantation and effective alternative to unrelated donor transplantation in patients
administration of cyclophosphamide after hematopoietic cell transplan- without matched sibling donors. Biol Blood Marrow Transplant 21:1299,
tation. Biol Blood Marrow Transplant 19(10):1430–1438, 2013. 2015.
+
137. Ganguly S, Ross DB, Panoskaltsis-Mortari A, et al: Donor CD4 156. Grosso D, Carabasi M, Filicko-O’Hara J, et al: A 2-step approach to
+
Foxp3 regulatory T cells are necessary for posttransplantation myeloablative haploidentical stem cell transplantation: a phase 1/2 trial
cyclophosphamide-mediated protection against GVHD in mice. Blood performed with optimized T-cell dosing. Blood 118(17):4732–4739,
124(13):2131–2141, 2014. 2011.
138. Kanakry CG, Ganguly S, Zahurak M, et al: Aldehyde dehydrogenase 157. Grosso D, Gaballa S, Alpdogan O, et al: A two-step approach to
expression drives human regulatory T cell resistance to posttransplanta- myeloablative haploidentical transplantation: low nonrelapse mortality
tion cyclophosphamide. Sci Transl Med 5:211ra157, 2013. and high survival confirmed in patients with earlier stage disease. Biol
139. Emadi A, Jones RJ, Brodsky RA: Cyclophosphamide and cancer: golden Blood Marrow Transplant 21:646, 2015.
anniversary. Nat Rev Clin Oncol 6(11):638–647, 2009. 158. Raj K, Pagliuca A, Bradstock K, et al: Peripheral blood hematopoietic
140. Darrasse-Jèze G, Bergot AS, Durgeau A, et al: Tumor emergence is stem cells for transplantation of hematological diseases from related,
hi
sensed by self-specific CD44 memory Tregs that create a dominant haploidentical donors after reduced-intensity conditioning. Biol Blood
tolerogenic environment for tumors in mice. J Clin Invest 119(9):2648– Marrow Transplant 20(6):890–895, 2014.
2662, 2009. 159. Castagna L, Crocchiolo R, Furst S, et al: Bone marrow compared with
141. Stokes J, Hoffman EA, Zeng Y, et al: Post-transplant bendamustine peripheral blood stem cells for haploidentical transplantation with a
reduces GvHD while preserving GvL in experimental haploidentical nonmyeloablative conditioning regimen and post-transplantation
bone marrow transplantation. Br J Haematol 174(1):102–116, 2016. cyclophosphamide. Biol Blood Marrow Transplant 20(5):724–729,
142. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al: Immune 2014.
reconstitution without graft-versus-host disease after haemopoietic 160. Anasetti C, Logan BR, Lee SJ, et al: Peripheral-blood stem cells versus
stem-cell transplantation: a phase 1/2 study. Lancet 360(9327):130–137, bone marrow from unrelated donors. N Engl J Med 367(16):1487–1496,
2002. 2012.